Catalysts · TEVA · CIK 818686 · page 2 of 2

TEVA catalysts and FDA events, page 2.

Updated Snapshot 20261116T222116ZBuilt

The next PDUFA date, the soonest catalysts with their source quotes and the latest FDA decisions are on TEVA PDUFA dates and upcoming catalysts. This page continues the list.

Past catalysts and FDA decisions (continued)

DateDrugCompanyEventIndicationStatusSource
October 22, 2024SELARSDITEVAFDA approval—ApprovedSEC 8-K Exhibit 99.1
Jul 2024Month disclosedAUSTEDO (deutetrabenazine)TEVAFDA approval—ApprovedSEC 8-K Exhibit 99.1
May 2024Month disclosedAUSTEDO (deutetrabenazine)TEVAFDA approval—ApprovedSEC 8-K Exhibit 99.1
April 16, 2024WEZLANA® (ustekinumab)TEVAFDA approval—ApprovedSEC 8-K Exhibit 99.1
February 24, 2024AMJEVITA® (adalimumab)TEVAFDA approval—ApprovedSEC 8-K Exhibit 99.1
February 24, 2024SIMLANDI®TEVAFDA approval—ApprovedSEC 8-K Exhibit 99.1
November 29, 2023Alvaiz (eltrombopag choline)TEVAFDA approval—ApprovedopenFDA Drugs@FDA
November 21, 2023TAXOL® (paclitaxel)TEVALabel expansion—ApprovedopenFDA Drugs@FDA
May 11, 2023TAXOL® (paclitaxel)TEVAFDA approval—ApprovedopenFDA Drugs@FDA
April 28, 2023UZEDY (risperidone)TEVAFDA approvalschizophrenia in adultsApprovedSEC 8-K Exhibit 99.1
February 17, 2023AUSTEDO (deutetrabenazine)TEVAFDA approval—ApprovedSEC 8-K Exhibit 99.1
April 15, 2022UZEDY (risperidone)TEVAComplete Response Letter—CRL issuedFDA Complete Response Letters
July 30, 2021Micafungin In Sodium Chloride 0.9% (micafungin sodium)TEVAFDA approval—ApprovedopenFDA Drugs@FDA
July 9, 2021Airduo Digihaler (fluticasone propionate; salmeterol xinafoate)TEVALabel expansion—ApprovedopenFDA Drugs@FDA
July 9, 2021Armonair Respiclick (fluticasone propionate)TEVALabel expansion—ApprovedopenFDA Drugs@FDA
June 24, 2021AUSTEDO (deutetrabenazine)TEVALabel expansion—ApprovedopenFDA Drugs@FDA
March 13, 2020Romidepsin (romidepsin)TEVAFDA approval—ApprovedopenFDA Drugs@FDA
January 27, 2020Ajovy (fremanezumab-vfrm)TEVALabel expansion—ApprovedopenFDA Drugs@FDA
September 5, 2019Fosaprepitant Dimeglumine (fosaprepitant dimeglumine)TEVAFDA approval—ApprovedopenFDA Drugs@FDA
September 14, 2018Ajovy (fremanezumab-vfrm)TEVAFDA approval—ApprovedopenFDA Drugs@FDA
September 7, 2018Cassipa (buprenorphine hydrochloride; naloxone hydrochloride)TEVAFDA approval—ApprovedopenFDA Drugs@FDA
October 26, 2017Faslodex (fulvestrant)TEVAComplete Response Letter—CRL issuedFDA Complete Response Letters
August 30, 2017AUSTEDO (deutetrabenazine)TEVAFDA approval—ApprovedopenFDA Drugs@FDA
June 2, 2017Romidepsin (romidepsin)TEVAComplete Response Letter—CRL issuedFDA Complete Response Letters
April 3, 2017AUSTEDO (deutetrabenazine)TEVAFDA approval—ApprovedopenFDA Drugs@FDA
January 27, 2017Airduo Digihaler (fluticasone propionate; salmeterol xinafoate)TEVAFDA approval—ApprovedopenFDA Drugs@FDA
January 27, 2017Armonair Respiclick (fluticasone propionate)TEVAFDA approval—ApprovedopenFDA Drugs@FDA
January 17, 2017Vantrela Er (hydrocodone bitartrate)TEVAFDA approval—ApprovedopenFDA Drugs@FDA
September 30, 2016Cassipa (buprenorphine hydrochloride; naloxone hydrochloride)TEVAComplete Response Letter—CRL issuedFDA Complete Response Letters
June 1, 2016Romidepsin (romidepsin)TEVAComplete Response Letter—CRL issuedFDA Complete Response Letters
May 27, 2016AUSTEDO (deutetrabenazine)TEVAComplete Response Letter—CRL issuedFDA Complete Response Letters
March 23, 2016Cinqair (reslizumab)TEVAFDA approval—ApprovedopenFDA Drugs@FDA
February 28, 2011Milprosa (progesterone)TEVAComplete Response Letter—CRL issuedFDA Complete Response Letters
Every catalyst is quoted from TEVA’s SEC filings, FDA records or ClinicalTrials.gov; each row links its primary source. Dates move; the linked filing is authoritative. Not investment advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.